Published in PLoS One on December 16, 2016
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (2009) 77.71
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 9.27
One-sample multiple testing procedure for phase II clinical trials. Biometrics (1982) 6.45
Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med (2014) 6.10
Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and Heart. J Thorac Oncol (2015) 5.83
Follow-up study of thymomas with special reference to their clinical stages. Cancer (1981) 5.75
Malignant thymoma in the United States: demographic patterns in incidence and associations with subsequent malignancies. Int J Cancer (2003) 4.02
Thymic tumors. Ann Thorac Surg (2004) 3.05
Thymic carcinoma outcomes and prognosis: results of an international analysis. J Thorac Cardiovasc Surg (2014) 2.58
The Masaoka-Koga stage classification for thymic malignancies: clarification and definition of terms. J Thorac Oncol (2011) 2.31
Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol (2004) 2.11
Opportunities in somatostatin research: biological, chemical and therapeutic aspects. Nat Rev Drug Discov (2003) 2.11
New WHO histologic classification predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer (2002) 1.93
Neoadjuvant chemoradiotherapy for locally advanced thymic tumors: a phase II, multi-institutional clinical trial. J Thorac Cardiovasc Surg (2013) 1.70
In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy. J Nucl Med (1998) 1.64
Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity. Neurology (1983) 1.53
Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res (1994) 1.53
Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol (1994) 1.51
Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol (2011) 1.25
Thymoma and paraneoplastic myasthenia gravis. Autoimmunity (2010) 1.21
The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol (2015) 1.20
Myasthenic and nonmyasthenic thymoma. An expansion of a minor cortical epithelial cell subset? Am J Pathol (1987) 1.18
Octreotide alone or with prednisone in patients with advanced thymoma and thymic carcinoma: an Eastern Cooperative Oncology Group Phase II Trial. J Clin Oncol (2004) 1.17
Thymoma and thymic carcinoma: molecular pathology and targeted therapy. J Thorac Oncol (2010) 1.16
Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther (1993) 1.08
Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS One (2012) 1.05
Somatostatin gene expression in the thymus gland. J Immunol (1989) 1.00
Somatostatin analogs: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs (1997) 0.98
Multimodal management of stages III-IVa malignant thymoma. Lung Cancer (2004) 0.91
Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone. N Engl J Med (1997) 0.91
Somatostatin analogs and prednisone in advanced refractory thymic tumors. Cancer (2002) 0.91
Thymoma and thymic carcinomas. Crit Rev Oncol Hematol (2016) 0.90
A practical guide from the International Thymic Malignancy Interest Group (ITMIG) regarding the radiographic assessment of treatment response of thymic epithelial tumors using modified RECIST criteria. J Thorac Oncol (2014) 0.89
Management of stage I and II thymoma. Thorac Surg Clin (2011) 0.89
Effect of ACTH on thymic masses. J Clin Endocrinol Metab (1952) 0.87
High prevalence of infections and autoimmunity in patients with thymoma. Hum Immunol (2011) 0.84
Thymoma-a clinico-pathological long-term study with emphasis on histology and adjuvant radiotherapy dose. J Thorac Oncol (2012) 0.84
Preoperative steroid pulse therapy for invasive thymoma: clinical experience and mechanism of action. Cancer (2006) 0.82
Somatostatin receptor scintigraphy in thymoma imaging method and clinical application. Pathol Res Pract (1999) 0.81
Chemotherapy of malignant thymoma. Case report and review of the literature. Cancer (1986) 0.81
Complete regression of a thymoma to glucocorticoids, commenced for palliation of symptoms. Eur J Cardiothorac Surg (2007) 0.81
Presence of glucocorticoid receptors in cultured thymic epithelial cells. Cell Immunol (1986) 0.80
Somatostatin receptor scintigraphy and somatostatin therapy in the evaluation and treatment of malignant thymoma. Clin Nucl Med (1999) 0.79
Multimodal treatment of metastatic thymic carcinoma including high-dose chemotherapy with autologous stem cell transplantation: report of a case with more than 4-year disease-free survival. Am J Clin Oncol (2001) 0.79
Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society. J Neurol (2016) 0.94
Regulatory function of CD4+CD25++ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-Dihydroxyvitamin D3 modulates the suppressor activity. J Neuroimmunol (2015) 0.86
Continuous representation of tumor microvessel density and detection of angiogenic hotspots in histological whole-slide images. Oncotarget (2015) 0.85
Survivin as a potential mediator to support autoreactive cell survival in myasthenia gravis: a human and animal model study. PLoS One (2014) 0.83
Differential Cytokine Changes in Patients with Myasthenia Gravis with Antibodies against AChR and MuSK. PLoS One (2015) 0.80
Thoracic rat spinal cord contusion injury induces remote spinal gliogenesis but not neurogenesis or gliogenesis in the brain. PLoS One (2014) 0.76
Myopathy in Childhood Muscle-Specific Kinase Myasthenia Gravis. Pediatr Neurol (2016) 0.75
Vascular architecture as diagnostic marker for differentiation of WHO thymoma subtypes and thymic carcinoma. Histopathology (2016) 0.75
AB thymoma with atypical type A component with delayed multiple lung and brain metastases. J Thorac Dis (2017) 0.75
Genetic heterogeneity within the HLA region in three distinct clinical subgroups of myasthenia gravis. Clin Immunol (2016) 0.75
Increased cFLIP expression in thymic epithelial tumors blocks autophagy via NF-κB signalling. Oncotarget (2017) 0.75
Metastatic type A thymoma: morphologic and genetic correlation. Histopathology (2016) 0.75
Fulminant Acute Ascending Hemorrhagic Myelitis Treated with Eculizumab. Front Neurol (2017) 0.75